Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Experimental study on immunotherapy with dendritic cell in leukemic mice model].

Xiang-xin Li1, Xue-liang Chen, Dao-xin Ma

  • 1Department of Hematology, Qilu Hospital, Shandong University, Jinan 250012, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|May 31, 2006
PubMed
Summary

Immunotherapy using dendritic cells (DCs) pulsed with leukemia antigens, combined with T cells, significantly reduced relapse rates and improved survival in mice after allogeneic bone marrow transplantation (allo-BMT). This approach enhances the graft-versus-leukemia (GVL) effect, offering a promising strategy for leukemia treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Photocaged Fluorogenic Glycoprobes for Light-Activatable Sensing and Imaging of Galactosidase Activities in Live Cells.

ACS sensors·2026
Same author

Comprehensive first-principles study of group IIIA-VIA A<sub>2</sub>B<sub>3</sub> two-dimensional ferroelectrics.

Physical chemistry chemical physics : PCCP·2026
Same author

Synthesis of divalent galactosyl and fucosyl spiropyran derivatives for the targeted inhibition of bacterial biofilms.

Chemical communications (Cambridge, England)·2026
Same author

A Time-Resolved In Situ SAXS Method for Real-Time Monitoring of Lipid Nanoparticles Assembly.

Membranes·2026
Same author

Artificial intelligence-assisted phenotyping of drug-resistant bacteria using a monosaccharide-based fluorescent sensor array.

Chemical science·2026
Same author

Real-World Evidence on Different Amoxicillin-Containing Regimens for <i>Helicobacter pylori</i> Treatment in Elderly Patients: Analysis of Efficacy, Safety, and Virulence Gene Association.

Antibiotics (Basel, Switzerland)·2026

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Context:

  • Allogeneic bone marrow transplantation (allo-BMT) is a critical treatment for hematological malignancies.
  • Leukemia relapse remains a significant challenge post-allo-BMT, necessitating strategies to enhance graft-versus-leukemia (GVL) effects.
  • Dendritic cells (DCs) are potent antigen-presenting cells that can be engineered for immunotherapy.

Purpose:

  • To evaluate the feasibility and efficacy of immunotherapy using leukemia antigen-pulsed dendritic cells (DCs) combined with T cells in a murine model of leukemia following allo-BMT.
  • To assess the impact of this combined immunotherapy on survival rates, relapse incidence, graft-versus-host disease (GVHD), and immune responses.

Summary:

  • Mature DCs were generated from bone marrow mononuclear cells (MNCs) and pulsed with leukemia-specific antigens.

Related Experiment Videos

  • Mice with leukemia underwent allo-BMT and were subsequently treated with either T cells alone or DCs plus T cells.
  • The combination of DCs and T cells resulted in a 0% relapse rate and a 70% long-term survival rate, significantly outperforming T cell monotherapy.
  • This immunotherapy enhanced specific cytotoxicity against leukemia cells and increased serum IL-2 levels, indicating a robust GVL effect without increasing GVHD incidence.

    • Impact:

    • This study demonstrates that immunotherapy with leukemia antigen-pulsed DCs and donor lymphocytes is an effective strategy to reinforce GVL activity and minimize leukemia recurrence after allo-BMT.
    • The findings suggest a potential therapeutic approach for improving outcomes in patients undergoing allo-BMT for leukemia.
    • Further research could explore optimizing DC-based immunotherapy protocols for clinical application in leukemia treatment.